169 related articles for article (PubMed ID: 27595938)
21. Structure of xylose reductase bound to NAD+ and the basis for single and dual co-substrate specificity in family 2 aldo-keto reductases.
Kavanagh KL; Klimacek M; Nidetzky B; Wilson DK
Biochem J; 2003 Jul; 373(Pt 2):319-26. PubMed ID: 12733986
[TBL] [Abstract][Full Text] [Related]
22. Purification and characterization of a novel erythrose reductase from Candida magnoliae.
Lee JK; Kim SY; Ryu YW; Seo JH; Kim JH
Appl Environ Microbiol; 2003 Jul; 69(7):3710-8. PubMed ID: 12839736
[TBL] [Abstract][Full Text] [Related]
23. Structure and characterization of a NAD(P)H-dependent carbonyl reductase from Pseudomonas aeruginosa PAO1.
Li S; Teng X; Su L; Mao G; Xu Y; Li T; Liu R; Zhang Q; Wang Y; Bartlam M
FEBS Lett; 2017 Jun; 591(12):1785-1797. PubMed ID: 28524228
[TBL] [Abstract][Full Text] [Related]
24. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY
Carcinogenesis; 2013 Sep; 34(9):2090-8. PubMed ID: 23689354
[TBL] [Abstract][Full Text] [Related]
25. Characterisation of a novel mouse liver aldo-keto reductase AKR7A5.
Hinshelwood A; McGarvie G; Ellis E
FEBS Lett; 2002 Jul; 523(1-3):213-8. PubMed ID: 12123834
[TBL] [Abstract][Full Text] [Related]
26. Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.
Cousido-Siah A; Ruiz FX; Mitschler A; Porté S; de Lera ÁR; Martín MJ; Manzanaro S; de la Fuente JA; Terwesten F; Betz M; Klebe G; Farrés J; Parés X; Podjarny A
Acta Crystallogr D Biol Crystallogr; 2014 Mar; 70(Pt 3):889-903. PubMed ID: 24598757
[TBL] [Abstract][Full Text] [Related]
27. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.
Wang C; Yan R; Luo D; Watabe K; Liao DF; Cao D
J Biol Chem; 2009 Sep; 284(39):26742-8. PubMed ID: 19643728
[TBL] [Abstract][Full Text] [Related]
28. Molecular chaperones maximize the native state yield on biological times by driving substrates out of equilibrium.
Chakrabarti S; Hyeon C; Ye X; Lorimer GH; Thirumalai D
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10919-E10927. PubMed ID: 29217641
[TBL] [Abstract][Full Text] [Related]
29. Pathophysiological roles of autophagy and aldo-keto reductases in development of doxorubicin resistance in gastrointestinal cancer cells.
Matsunaga T; Kawabata S; Yanagihara Y; Kezuka C; Kato M; Morikawa Y; Endo S; Chen H; Iguchi K; Ikari A
Chem Biol Interact; 2019 Dec; 314():108839. PubMed ID: 31563593
[TBL] [Abstract][Full Text] [Related]
30. Metabolism of gamma hydroxybutyrate in human hepatoma HepG2 cells by the aldo-keto reductase AKR1A1.
Alzeer S; Ellis EM
Biochem Pharmacol; 2014 Dec; 92(3):499-505. PubMed ID: 25256836
[TBL] [Abstract][Full Text] [Related]
31. Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis.
Matsunaga T; Endo S; Soda M; Zhao HT; El-Kabbani O; Tajima K; Hara A
Biochem Biophys Res Commun; 2009 Nov; 389(1):128-32. PubMed ID: 19706287
[TBL] [Abstract][Full Text] [Related]
32. The structure of apo and holo forms of xylose reductase, a dimeric aldo-keto reductase from Candida tenuis.
Kavanagh KL; Klimacek M; Nidetzky B; Wilson DK
Biochemistry; 2002 Jul; 41(28):8785-95. PubMed ID: 12102621
[TBL] [Abstract][Full Text] [Related]
33. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Ma J; Yan R; Zu X; Cheng JM; Rao K; Liao DF; Cao D
J Biol Chem; 2008 Feb; 283(6):3418-3423. PubMed ID: 18056116
[TBL] [Abstract][Full Text] [Related]
34. Identification of a determinant for strict NADP(H)-specificity and high sensitivity to mixed-type steroid inhibitor of rabbit aldo-keto reductase 1C33 by site-directed mutagenesis.
Endo S; Matsunaga T; Ikari A; El-Kabbani O; Hara A; Kitade Y
Arch Biochem Biophys; 2015 Mar; 569():19-25. PubMed ID: 25660042
[TBL] [Abstract][Full Text] [Related]
35. Aldo Keto Reductases AKR1B1 and AKR1B10 in Cancer: Molecular Mechanisms and Signaling Networks.
Banerjee S
Adv Exp Med Biol; 2021; 1347():65-82. PubMed ID: 33945128
[TBL] [Abstract][Full Text] [Related]
36. Effects of aldo-keto reductase family 1 member A on osteoblast differentiation associated with lactate production in MC3T3-E1 preosteoblastic cells.
Kuo CH; Lee IC; Huang BJ; Chen CM; Liou YM
Biochem Cell Biol; 2022 Oct; 100(5):413-424. PubMed ID: 35858481
[TBL] [Abstract][Full Text] [Related]
37. The residual pro-part of cathepsin C fulfills the criteria required for an intramolecular chaperone in folding and stabilizing the human proenzyme.
Cigić B; Dahl SW; Pain RH
Biochemistry; 2000 Oct; 39(40):12382-90. PubMed ID: 11015218
[TBL] [Abstract][Full Text] [Related]
38. Procollagen triple helix assembly: an unconventional chaperone-assisted folding paradigm.
Makareeva E; Leikin S
PLoS One; 2007 Oct; 2(10):e1029. PubMed ID: 17925877
[TBL] [Abstract][Full Text] [Related]
39. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Endo S; Matsunaga T; Mamiya H; Ohta C; Soda M; Kitade Y; Tajima K; Zhao HT; El-Kabbani O; Hara A
Arch Biochem Biophys; 2009 Jul; 487(1):1-9. PubMed ID: 19464995
[TBL] [Abstract][Full Text] [Related]
40. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Zhang W; Li H; Yang Y; Liao J; Yang GY
Cancer Lett; 2014 Dec; 355(2):273-80. PubMed ID: 25304374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
